Last edition
News about "Min Xu"
Harbour BioMed Publishes Positive Phase I Data for HBM9378 in Immunology
Harbour BioMed reports favourable safety and pharmacokinetic profile for HBM9378 in Phase I trial, supporting further development for severe immunological disorders.
Min Xu | 23/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members